Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Investing Activities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Cash from Investing Activities for 10 consecutive years, with -$72.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 170.48% to -$72.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $236.0 million, a 1411.11% increase, with the full-year FY2025 number at $236.0 million, up 1411.11% from a year prior.
  • Cash from Investing Activities was -$72.2 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $117.2 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $119.9 million in Q1 2025 to a low of -$275.5 million in Q3 2024.
  • A 5-year average of -$5.1 million and a median of $62.4 million in 2023 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: soared 397.91% in 2023, then crashed 528.5% in 2024.
  • Ultragenyx Pharmaceutical's Cash from Investing Activities stood at $69.1 million in 2021, then plummeted by 348.49% to -$171.6 million in 2022, then surged by 37.64% to -$107.0 million in 2023, then surged by 195.78% to $102.5 million in 2024, then crashed by 170.48% to -$72.2 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash from Investing Activities are -$72.2 million (Q4 2025), $117.2 million (Q3 2025), and $71.2 million (Q2 2025).